News
An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...
Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...
Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...
Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...
16h
Zacks Investment Research on MSNModerna Stock Gains on Encouraging Flu Vaccine DataModerna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...
Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...
Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
S&P 500 surges in H1 2025; explore AI leaders & ETFs for H2. Click to learn more about stocks to avoid and tips to navigate ...
Opioid addicts covered by Medicare and Medicaid are less likely to receive the mental health and substance use treatment that ...
7h
Daily Maverick on MSNDon’t panic about new SARS-CoV-2 variant, experts sayCovid has largely dropped out of the headlines, but the virus that causes it is still circulating. We ask what we should know about a new variant of SARS-CoV-2, the state of the Covid pandemic in 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results